MAP2K7 and melanoma: For this kind of tumor, recently the FDA also approved the combination of encorafenib (a BRAF inhibitor) and binimetinib (a MEK inhibitor), and this combination is able to improve PFS and OS in patients with BRAF-mutated melanoma [99].